New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
Revenue from operations up 26% to Rs. 768 crores
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)